Proamatine
NDC Package 54092-003-01
Package Information
Proamatine is a . Marketed by Takeda Pharmaceuticals America, Inc., this product is identified by NDC 54092-003 and is authorized under FDA application NDA019815.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 54092 - Takeda Pharmaceuticals America, Inc.
- 54092-003 - Proamatine
- 54092-003-01 - 100 TABLET in 1 BOTTLE
- 54092-003 - Proamatine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 54092-003-01 identifies a specific commercial package of 100 tablet in 1 bottle of Proamatine, labeled by Takeda Pharmaceuticals America, Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Takeda Pharmaceuticals America, Inc. on September 06, 1996. The current certification is valid through December 31, 2010.
How is this Takeda Pharmaceuticals America, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 54092000301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.